Abstract
Fragile X-associated tremor and ataxia syndrome (FXTAS) is a progressive neurodegenerative disorder (1) of late onset that occurs among the premutation carriers of the FMR1 (Fragile X mental retardation 1) gene; which is also associated with Fragile X Syndrome (FXS). FXTAS is characterized by neurologic deficits that include progressive intention tremor, cerebellar ataxia, parkinsonism, peripheral neuropathy, cognitive deficits in memory and executive function, and autonomic dysfunction.
FXTAS is emerging as an important diagnostic option for men with tremor, gait disorders and neurodegenerative symptoms. In general there is a subdiagnosis of this disease as it is a recently described syndrome and because of the lack of knowledge from health professionals; whom, due to the similarity of their clinical presentation with other neurological disorders, generally tend to confuse the diagnosis.
In Colombia the prevalence of FXS or FXTAS has not been documented. However, a township in Valle del Cauca has a prevalence of more than 100 times the worldwide prevalence of FXS reported in the literature, which suggests that in Colombia there is underreporting of FXS and FXTAS.
This review aims to disseminate the advances in knowledge of the clinical manifestations, the neurophysiopathology and treatment options for patients with FXTAS; and thus increase diagnosis and contribute to improving the quality of life of those affected and their families.
References
HAGERMAN R, HAGERMAN P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol. 2013, Aug;12(8):78698 [citado 2014 marzo 20]. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3922535&tool=pmcentrez&rendertype=abstract.
BERRY-KRAVIS E, ABRAMS L, COFFEY SM, HALL DA, GRECO C, GANE LW, ET AL. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord [Internet]. 2007, Jul;22(14):2018-30. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17618523.
SELTZER MM, BAKER MW, HONG J, MAENNER M, GREENBERG J, MANDEL D. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B Neuropsychiatr Genet. 2012, Jul;159B(5):589-97 [citado 2014 marzo 20]. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3391968&tool=pmcentrez&rendertype=abstract.
BOURGEOIS JA, COGSWELL JB, HESSL D, ZHANG L, ONO MY, TASSONE F, ET AL. Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. Gen Hosp Psychiatry 2007;29(4):349-56 [citado 2014 abril 16]. Disponible en: http://www.ncbi.nlm.nih.gov/ pubmed/17591512.
HALL DA, O'KEEFE JA. Clinical neurogenetics: fragile x-associated tremor/ataxia syndrome. Neurol Clin. 2013, Nov;31(4):1073-84 [citado 2014 abril 15]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24176424.
BERRY-KRAVIS E, ABRAMS L, COFFEY SM, HALL DA, GRECO C, GANE LW, ET AL. Fragile X-Associated Tremor / Ataxia Syndrome: Clinical Features, Genetics, and Testing Guidelines 2007;22(14):2018-30.
SALDARRIAGA W, TASSONE F, GONZÁLEZ LY, FORERO JV, AYALA S, HAGERMAN R. Fragile X Syndrome [Internet]. Colombia Médica; 2014. p. 190-8. Disponible en: http://colombiamedica.univalle.edu.co/index.php/comedica/article/view/1810/2577 Consultado en abril 9 de 2015.
BAGNI C, TASSONE F, NERI G, HAGERMAN R. Science in medicine Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics 2012;122(12).
LIU Y, WINARNI T, ZHANG L, TASSONE F, HAGERMAN R. Fragile X-associated tremor/ataxia syndrome (FXTAS) in grey zone carriers. Clin Genet. 2013;84:74-7.
HALL D, TASSONE F, KLEPITSKAYA O, LEEHEY M. Fragile X Associated Tremor ataxia syndrome in FMR1 gray zone allele carriers. Movement Disorders; 2012. p. 297-301.
PRETTO DI, HUNSAKER MR, CUNNINGHAM CL, GRECO CM, HAGERMAN RJ, NOCTOR SC, ET AL. Intranuclear inclusions in a fragile X mosaic male. Transl Neurodegener. 2013;2:10 [Internet]. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3668897&tool=pmcentrez&rendertype=abstract.
LOESCH DZ, SHERWELL S, KINSELLA G, TASSONE F, TAYLOR A, AMOR D, ET AL. Fragile X-associated tremor/ataxia phenotype in a male carrier of unmethylated full mutation in the FMR1 gene. Clin Genet. 2012;82:88-92.
FERNÁNDEZ-CARVAJAL I, WALICHIEWICZ P, XIAOSEN X, PAN R, HAGERMAN PJ, TASSONE F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn. 2009, Jul;11(4):324-9 [citado 2014 marzo 25]. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2710709&tool=pmcentrez&rendertype=abstract.
TOLEDANO-ALHADEF H, BASEL-VANAGAITE L, MAGAL N, DAVIDOV B, EHRLICH S, DRASINOVER V, ET AL. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet [Internet]. 2001, Aug;69(2):351-60. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1235307&tool=pmcentrez&rendertype=abstract.
PIROZZI F, TABOLACCI E, NERI G. The FRAXopathies: definition, overview, and update. Am J Med Genet A. 2011, Aug;155A(8):1803-16. [citado 2014 abril 16]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21739597.
LEEHEY MA. Fragile X Y Associated Tremor / Ataxia Syndrome: Clinical Phenotype, Diagnosis, and Treatment. 2009;57(8):830-6.
WANG JY, HAGERMAN RJ, RIVERA SM. A multimodal imaging analysis of subcortical gray matter in fragile X premutation carriers. Mov Disord. 2013, Aug;28(9):1278-84 [citado 2014 abril 16]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23649693.
BOURGEOIS JA, SERITAN AL, CASILLAS EM, HESSL D, SCHNEIDER A, YANG Y, ET AL. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry 2011, Feb;72(2):175-82 [citado 2014 marzo 20]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20816038.
JACQUEMONT S, HAGERMAN RJ, LEEHEY MA, HALL DA, LEVINE RA, BRUNBERG JA, ET AL. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004;291:460-9.
HAGERMAN RJ, LEEHEY M, HEINRICHS W, TASSONE F, WILSON R, HILLS J, ET AL. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001, Jul;57(1):127-30 [citado 2015 julio 13]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/11445641.
HAGERMAN P. Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms. Acta Neuropathol. 2013, Jul;126(1):1-19 [citado 2014 abril 15]. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3904666&tool=pmcentrez&rendertype=abstract.
GRECO CM, BERMAN RF, MARTIN RM, TASSONE F, SCHWARTZ PH, CHANG A, ET AL. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006;129:243-55.
GRECO CM, HAGERMAN RJ, TASSONE F, CHUDLEY AE, BIGIO MR DEL, JACQUEMONT S, ET AL. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002, Aug;125(Pt 8):1760-71. [Internet]. Disponible en: http://www.ncbi.nlm.nih gov/pubmed/12135967.
TASSONE F, GRECO CM, HUNSAKER MR, SERITAN AL, BERMAN RF, GANE LW, ET AL. Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes Brain Behav. 2012;11:577-85. [Internet]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22463693.
HUNSAKER MR, GRECO CM, SPATH MA, SMITS APT, NAVARRO CS, TASSONE F, ET AL. Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathol. 2011;122:467-79.
HAGERMAN P. Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms. Acta Neuropathol. 2013;126:1-19. [Internet]. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3904666&tool=pmcentrez&rendertype=abstract.
TASSONE F, HAGERMAN RJ, CHAMBERLAIN WD, HAGERMAN PJ. Transcription of the FMR1 gene in individuals with fragile X syndrome. Am J Med Genet. 2000;97:195-203.
TASSONE F, HAGERMAN RJ, LOESCH DZ, LACHIEWICZ A, TAYLOR AK, HAGERMAN PJ. Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet. 2000;94:232-6.
KENNESON A, ZHANG F, HAGEDORN CH, WARREN ST. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet. 2001;10:1449-54.
CHEN Y, TASSONE F, BERMAN RF, HAGERMAN PJ, HAGERMAN RJ, WILLEMSEN R, ET AL. Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet. 2009;19(1):196-208.
LOZANO R, SUMMERS S, LOZANO C, MU Y, HESSL D, NGUYEN D, ET AL. Association between macroorchidism and intelligence in FMR1 premutation carriers. Am J Med Genet A. 2014, Jun;1-6 [citado 2014 junio 11]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24903624.
GARCÍA-AROCENA D, HAGERMAN PJ. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet. 2010;19.
CHONCHAIYA W, AU J, SCHNEIDER A, HESSL D, HARRIS SW, LAIRD M, ET AL. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Hum Genet. 2012;131:581-9.
FARZIN F, PERRY H, HESSL D, LOESCH D, COHEN J, BACALMAN S, ET AL. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr. 2006;27:S137-44.
ECHEVERRÍA GV, COOPER TA. RNA-binding proteins in microsatellite expansion disorders: Mediators of RNA toxicity. Brain Research; 2012. p. 100-11.
UDD B, KRAHE R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 2012;11:891-905. [Internet]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22995693.
SOFOLA OA, JIN P, QIN Y, DUAN R, LIU H, HARO M DE, ET AL. RNA-Binding Proteins hnRNP A2/B1 and CUGBP1 Suppress Fragile X CGG Premutation Repeat-Induced Neurodegeneration in a Drosophila Model of FXTAS. Neuron. 2007;55:565-71.
AUMILLER V, GRAEBSCH A, KREMMER E, NIESSING D, FÖRSTEMANN K. Drosophila Pur-? binds to trinucleotide-repeat containing cellular RNAs and translocates to the early oocyte. RNA Biology; 2012. p. 633-43.
JIN P, DUAN R, QURASHI A, QIN Y, TIAN D, ROSSER TC, ET AL. Pur ? Binds to rCGG Repeats and Modulates Repeat-Mediated Neurodegeneration in a Drosophila Model of Fragile X Tremor/Ataxia Syndrome. Neuron. 2007;55:556-64.
SELLIER C, RAU F, LIU Y, TASSONE F, HUKEMA RK, GATTONI R, ET AL. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J. 2010;29:1248-61.
DENLI AM, TOPS BBJ, PLASTERK RHA, KETTING RF, HANNON GJ. Processing of primary microRNAs by the Microprocessor complex. Nature 2004;432:231-5.
SELLIER C, FREYERMUTH F, TABET R, TRAN T, HE F, RUFFENACH F, ET AL. Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep. 2013, Mar;3(3):869-80 [citado 2014 marzo 24]. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3639429&tool=pmcentrez&rendertype=abstract.
AMERES SL, ZAMORE PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. Nature Publishing Group 2013, Aug;14(8):475-88. [citado 2014 marzo 19]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23800994.
WANG D, YANG B. MicroRNA expression detection methods. Vasa; 2010 [citado 2014 abril 17]. Disponible en: http://medcontent.metapress.com/index/A65RM03P4874243N.pdf.
RENOUX AJ, TODD PK. Neurodegeneration the RNA way. Progress in Neurobiology; 2012. p. 173-89.
KING OD, GITLER AD, SHORTER J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Research; 2012. p. 61-80.
TODD PK, OH S, KRANS A, HE F, SELLIER C, FRAZER M, ET AL. CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neurol. 2013;78:440-55.
LEEHEY MA, BERRY-KRAVIS E, MIN S-J, HALL DA, RICE CD, ZHANG L, ET AL. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord. 2007, Jan;22(2):203-6 [citado 2014 abril 16]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17133502.
HAGERMAN RJ, HALL DA, COFFEY S, LEEHEY M, BOURGEOIS J, ZHANG L, ET AL. Treatment of fragile X-associated tremor ataxia syndrome ( FXTAS ) and related neurological problems 2008;3(2):251-62.
HALL DA, BERRY-KRAVIS E, HAGERMAN RJ, HAGERMAN PJ, RICE CD, LEEHEY MA. Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord. 2006, Oct;21(10):1741-4 [citado 2014 abril 16]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16773616.
HAGERMAN RJ, LEAVITT BR, FARZIN F, JACQUEMONT S, GRECO CM, BRUNBERG JA, ET AL. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet. 2004, May;74(5):1051-6. [Internet]. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1181968&tool=pmcentrez&rendertype=abstract.
ORTIGAS MC, BOURGEOIS JA, SCHNEIDER A, OLICHNEY J, NGUYEN DV, COGSWELL JB, ET AL. Improving Fragile X-Associated Tremor/Ataxia Syndrome Symptoms With Memantine and Venlafaxine. J Clin Psychopharmacol.; 2010. p. 642-4.
SERITAN AL, NGUYEN DV, MU Y, TASSONE F, BOURGEOIS JA, SCHNEIDER A, ET AL. Memantine for fragile X-associated tremor/ataxia syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2014, Mar;75(3):264-71.
CAO Z, HULSIZER S, TASSONE F, TANG H, HAGERMAN RJ, ROGAWSKI MA, ET AL. Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Hum Mol Genet. 2012, Jul;21(13):2923-35 [citado 2014 abril 16]. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3373240&tool=pmcentrez&rendertype=abstract.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.